#### DRUG SAFETY OVERSIGHT BOARD

### **Center for Drug Evaluation and Research**

### **Chair**

 Dr. Douglas Throckmorton, Acting Deputy Director, Center for Drug Evaluation and Research

### **Executive Secretary**

 Dr. Susan Cummins, Executive Director, Drug Safety Oversight Board, Center for Drug Evaluation and Research

# Office of New Drugs (OND)

# **Primary Members:**

- Dr. John Jenkins, Director, Office of New Drugs
- Dr. Florence Houn, Director, Office of Drug Evaluation III
- Dr. Debra Birnkrant, Director, Division of Anti-Viral Drug Products

#### Alternate Members:

- Dr. Sandra Kweder, Deputy Director, Office of New Drugs
- Dr. Robert Meyer, Director, Office of Drug Evaluation II

### Office of Drug Safety (ODS)

### **Primary Members:**

- Dr. Paul Seligman, Director, Office of Pharmacoepidemiology and Statistical Science
- Dr. Anne Trontell, Deputy Director, Office of Drug Safety
- Dr. Gerald Dal Pan, Director, Division of Surveillance, Research and Communication Support

# Alternate Members:

- Dr. Mark Avigan, Director, Division of Drug Risk Evaluation
- Dr. Carol Holquist, Director, Division of Medication Errors and Technical Support

# Office of Counter Terrorism and Pediatric Drug Development (OCTAP)

### Primary Member:

• Dr. Solomon Iyasu, Acting Deputy Director, Division of Pediatric Drug Development

### Alternate Member:

• Dr. Lewis Schrager, Team Leader, Division of Counterterrorism

# Office of Compliance (OC)

### Primary Member:

• Dr. Susan Allen, Associate Director, Scientific and Medical Affairs

### Alternate Member:

• David Horowitz, Director, Office of Compliance

### Office of Pharmaceutical Science (OPS)

### Primary Member:

• Dr. Dena Hixon, Associate Director for Medical Affairs, Office of Generic Drugs

# Alternate Member:

• Dr. Lawrence Yu, Director for Science

### Office of Clinical Pharmacology and Biopharmaceutics (OCPB)

# Primary Member:

• Dr. Lawrence Lesko, Director, Office of Clinical Pharmacology and Biopharmaceutics

### Alternate Member:

 Dr. Robert Powell, Senior Pharmacist, Office of Clinical Pharmacology and Biopharmaceutics

# Office of Biostatistics (OB)

#### **Primary Member:**

• Dr. Robert O'Neill, Director, Office of Biostatistics

#### Alternate Member:

• Dr. Charles Anello, Deputy Director, Office of Biostatistics

# **Office of Medical Policy**

• Dr. Robert Temple, Director, Office of Medical Policy (non-voting)

### **Center for Biologic Evaluation and Research**

### Primary Member:

• Dr. Karen Midthun, Deputy Director, Center for Biologic Evaluation and Research

#### Alternate Member:

• Dr. Miles Braun, Director, Division of Epidemiology

### **Center for Devices and Radiological Health**

#### Primary Member:

• Dr. Kimber Richter, Deputy Director for Medical Affairs, Office of Compliance

### Alternate Member:

• Dr. Thomas Gross, Division of Postmarket Surveillance

### **Department of Veterans Affairs**

### Primary Member:

 Dr. Chester B. Good, Staff Physician, Veterans Administration Pittsburgh Health Care System; Chairman, Medical Advisory Panel for Pharmacy Benefits Management, Department of Veterans Affairs

#### Alternate Member:

 Dr. Peter Glassman, Staff Physician, Veterans Administration Hospital of Greater Los Angeles and Co-Director, Center for Medication Safety, Department of Veterans Affairs

# National Institutes of Health, National Cancer Institute

# Primary Member:

• Dr. Anthony Murgo, Acting Chief, Investigational Drug Branch, Associate Chief for Developmental Chemotherapy Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis

# Alternate Member:

• Dr. Margaret Mooney, Clinical Investigations Branch ,Cancer Treatment Evaluation Program